MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopaminergic neurons"

  • 2022 International Congress

    CCL5 promotes Th17 migrating into SNpc by promoting Th17 proportion increase and LFA-1 expression

    XZ. Xue (WuHan, China)

    Objective: To explore the specific pathway by which CCL5 induces Th17 cells migrating into substantia nigra pars compacta (SNpc) to aggravate Parkinson's disease (PD). Background:…
  • 2022 International Congress

    Silencing dopamine neurons during sleep slows disease progression in parkinsonian mice

    C. Meng, G. Cui (Research Triangle Park, USA)

    Objective: To develop a treatment to stop or slow the progression of Parkinson's disease. Background: Parkinson’s disease (PD) is believed to be caused by the…
  • 2022 International Congress

    PP1α negatively regulates D2 receptor mediated cadmium induced motor dysfunctions: protective potential of Quercetin.

    R. Gupta, R. Shukla, V K. Khanna (LUCKNOW, India)

    Objective: The present study has been focused to identify the molecular targets that involved in Cadmium-induced motor dysfunctions. At the same time, we also focused…
  • 2022 International Congress

    Exenatide protects iPSC-derived dopaminergic neurons with A53T mutation through restoration of insulin signaling

    D. Athauda, J. Evans, A. Wernick, G. Virdi, M. Choi, K. D'Sa, Z. Shadman, N. Greig, T. Foltynie, S. Gandhi (London, United Kingdom)

    Objective: Here we sought to investigate mechanisms by which insulin resistance affects PD pathogenesis in-vitro, and whether restoration of insulin signaling, using GLP-1 agonist exenatide…
  • 2022 International Congress

    Protein aggregation and calcium dysregulation are the earliest hallmarks of synucleinopathy in enriched iPSC-derived human midbrain dopaminergic neurons

    G. Virdi, M. Choi, J. Evans, S. Strohbuecker, M. Horrocks, R. Patani, S. Gandhi (London, United Kingdom)

    Objective: Develop and adapt a differentiation paradigm to produce enriched hiPSC-derived midbrain dopaminergic neurons (mDA), to resolve the temporal sequence of pathophysiological events in synucleinopathies.…
  • 2022 International Congress

    Pharmacological activation of Rev-erbα Provides Neuroprotection against Parkinson’s Disease

    L. Kou (Wuhan, China)

    Objective: In this study, we investigated the effects of SR9009, a Rev-ERB agonist, on the dopaminergic system in the MPTP model of PD. Background: Circadian…
  • 2022 International Congress

    Level of glial neurotrophic factor in the blood plasma depending on the duration of Parkinson’s disease

    B. Muminov, R. Matmurodov, E. Abduqodirov (Tashkent, Uzbekistan)

    Objective: To study the level of glial neurotrophic factor in the blood plasma depending on the duration of PD. Background: Study of the biochemical aspects…
  • 2022 International Congress

    Evaluation of α-synuclein pathology and function in dopaminergic neurons derived from LRRK2 I1371V PD patient iPSCs

    I. Datta, S. Jagtap, C. Potdar (Bangalore, India)

    Objective: To evaluate cellular pathogenesis in DA neuron function, and α-synuclein pathology using LRRK2-I1371V PD iPSC. Background: It is reported for complex-neurodegenerative disorders like PD,…
  • 2022 International Congress

    Glial neurotrophic factor as an early diagnostic marker in Parkinson’s disease

    M. Matmurodov, A. Abduqodirov, L. Khalimova, B. Muminov (Tashkent, Uzbekistan)

    Objective: To study the level of glial neurotrophic disease in blood plasma in patients with Parkinson's disease (PD) Background: Glial neutrophic factor (GDNF) is a…
  • 2022 International Congress

    Smoking and Substantia Nigra Neuron Density in the Presence and Absence of Lewy Pathology

    G. Ross, R. Abbott, H. Petrovitch, J. Duda, J. Uyehara-Lock, K. Masaki, C. Tanner (Honolulu, USA)

    Objective: Our objective is to examine the association of mid-life smoking with post mortem substantia nigra (SN) neuron density in the presence and absence of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley